First Case of Teclistamab Treatment in a Jehovah’s Witness (JW) with Refractory Multiple Myeloma

Key Points

• Teclistamab demonstrated a significant response rate, achieving remission in the patient.
• The patient experienced manageable adverse effects, with no severe complications reported.
• This case supports the potential for immunotherapy to treat myeloma in patients with religious constraints.
• Further exploration is needed for broader applicability and understanding of treatment impacts.